These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32697335)

  • 1. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
    Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
    Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
    Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
    Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
    J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
    Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
    J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
    Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
    Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
    Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
    J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
    Cortes JE; Candoni A; Clark RE; Leber B; Montesinos P; Vyas P; Zeidan AM; Heuser M
    Leuk Lymphoma; 2020 Dec; 61(14):3287-3305. PubMed ID: 32967493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
    Goldsmith SR; Lovell AR; Schroeder MA
    Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
    Tremblay G; Daniele P; Bell T; Chan G; Brown A; Cappelleri JC
    J Comp Eff Res; 2021 May; 10(7):603-612. PubMed ID: 33733815
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
    Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
    J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
    Feld J; Silverman LR; Navada SC
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e415-e422. PubMed ID: 33547022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glasdegib in the treatment of acute myeloid leukemia.
    Wolska-Washer A; Robak T
    Future Oncol; 2019 Oct; 15(28):3219-3232. PubMed ID: 31432695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
    Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
    McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
    Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
    Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
    Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
    Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
    Cortes JE; Dombret H; Merchant A; Tauchi T; DiRienzo CG; Sleight B; Zhang X; Leip EP; Shaik N; Bell T; Chan G; Sekeres MA
    Future Oncol; 2019 Nov; 15(31):3531-3545. PubMed ID: 31516032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
    Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
    Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.